Northwest & Ethical Investments L.P. Purchases 9,623 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Northwest & Ethical Investments L.P. raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 4.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 244,195 shares of the biopharmaceutical company's stock after purchasing an additional 9,623 shares during the period. Northwest & Ethical Investments L.P.'s holdings in Gilead Sciences were worth $22,556,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Avior Wealth Management LLC boosted its position in Gilead Sciences by 1.2% during the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company's stock worth $782,000 after buying an additional 108 shares during the period. Southland Equity Partners LLC raised its stake in shares of Gilead Sciences by 3.6% during the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company's stock valued at $289,000 after acquiring an additional 110 shares during the last quarter. Berkshire Bank lifted its holdings in shares of Gilead Sciences by 3.4% during the fourth quarter. Berkshire Bank now owns 3,398 shares of the biopharmaceutical company's stock worth $314,000 after purchasing an additional 111 shares during the period. CFO4Life Group LLC increased its holdings in Gilead Sciences by 2.7% in the fourth quarter. CFO4Life Group LLC now owns 4,265 shares of the biopharmaceutical company's stock valued at $394,000 after purchasing an additional 112 shares during the period. Finally, GHP Investment Advisors Inc. increased its holdings in Gilead Sciences by 1.1% in the fourth quarter. GHP Investment Advisors Inc. now owns 11,354 shares of the biopharmaceutical company's stock valued at $1,049,000 after purchasing an additional 122 shares during the period. 83.67% of the stock is owned by institutional investors.

Remove Ads

Gilead Sciences Stock Down 0.3 %

GILD traded down $0.34 during mid-day trading on Monday, reaching $106.74. 8,562,938 shares of the stock were exchanged, compared to its average volume of 6,800,396. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. The stock has a market capitalization of $132.93 billion, a PE ratio of 288.49, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The company has a 50 day moving average price of $104.01 and a two-hundred day moving average price of $94.15.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be paid a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.96%. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences's payout ratio is presently 854.05%.

Insider Buying and Selling

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. This trade represents a 1.89 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last ninety days, insiders have sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research firms have commented on GILD. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price target on the stock in a research report on Thursday, February 13th. Piper Sandler upped their target price on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a report on Wednesday, February 12th. JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. BMO Capital Markets boosted their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Finally, Cantor Fitzgerald reiterated a "neutral" rating and set a $80.00 price objective on shares of Gilead Sciences in a research report on Wednesday, December 11th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus target price of $104.52.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.